Approval · Notice of Compliance 28039 · 2022
IMURAN: Notice of Compliance 28039
Issued April 27, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28039
- Date
- April 27, 2022
- Company
- Aspen Pharmacare Canada Inc.Oakville, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the Product Monograph (PM) with the post-market adverse reaction of erythema nodosum. In addition, the PM was converted to 2020 format.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IMURAN | Not yet assigned | — |
Medicinal ingredients
- AZATHIOPRINE SODIUM 50 MG per VIAL
- AZATHIOPRINE 50 MG per TAB